Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, boosting neuroscience portfolio
by Via AP news wire
Dec 22, 2023
1 minute
![](https://article-imgs.scribdassets.com/10ymhitn0gbtl1bq/images/fileTDPTL0ZM.jpg)
Drugmaker Bristol Myers Squibb is acquiring Karuna Therapeutics, a biopharmaceutical company that has developed a new antipsychotic, in a $14 billion deal.
Bristol Myers Squibb and Karuna announced their merger agreement on Friday. The transaction, which amounts to $330 per share
You’re reading a preview, subscribe to read more.
Start your free 30 days